AstraZeneca has struck a deal to combine its anti-PD-L1 drug with NewLink Genetics’ IDO pathway inhibitor. The collaborators will jointly fund a phase 2 trial of the combination in pancreatic cancer patients. http://www.fiercebiotech.com/biotech/astrazeneca-newlink-pen-pd-l1-and-ido-combination-pact
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn. http://www.biopharma-reporter.com/Upstream-Processing/Gilead-aims-to-expand-CAR-T-manufacturing-post-Kite-acquisition
Innovators will need to quantify value to bring costly drugs to market.
The post Real world data essential for CAR-T therapy success appeared first on Pharmaphorum. https://pharmaphorum.com/news/real-world-data-car-t/
But will need to play catch up in the US, where Novartis has a slight lead http://www.pmlive.com/pharma_news/kite_files_first_car-t_candidate_in_europe_1199899
Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel. http://www.pharmatimes.com/news/fda_panel_backs_novartis_car-t_therapy_ctl019_1198432
The pharma giant will pay the Chinese firm up to $980m in milestone payments http://www.pmlive.com/pharma_news/celgene_joins_pd-1_race_via_partnership_with_beigene_1197746
Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). http://www.worldpharmanews.com/merckgroup/3986-merck-ventures-creates-new-immuno-oncology-company-ionctura
US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed. http://www.in-pharmatechnologist.com/Regulatory-Safety/Approval-for-biomarker-based-Keytruda-a-US-FDA-first
(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Merck & Co’s immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.